The PCV13 (13-valent pneumococcal conjugate vaccine) uses carrier protein CRM197 conjugated to capsular polysaccharides. Compared to the 23-valent polysaccharide vaccine (PPSV23), what is the key immunological advantage of the conjugate vaccine in infants?

• A Conjugate vaccines produce higher IgM titres than polysaccharide vaccines
• B Conjugate vaccines provide broader serotype coverage than polysaccharide vaccines
• C Conjugate vaccines can be given orally unlike polysaccharide vaccines
• D Conjugate vaccines stimulate T-cell-dependent (TD) immune responses, producing immunological memory and IgG class switching in infants under 2 years ✓

Explanation

Pure polysaccharide vaccines are T-cell-independent (TI-2) antigens — they stimulate B cells directly without T-cell help, producing mainly IgM with no immunological memory and poor response in children under 2 years (whose B cells lack marginal zone populations capable of TI responses). Conjugating polysaccharides to carrier proteins (like CRM197, a non-toxic diphtheria toxin mutant) converts them into T-cell-dependent antigens, activating CD4+ Th cells, inducing class-switch recombination to IgG, generating germinal centre reactions, long-lived plasma cells, and memory B cells — providing durable protection and booster responses.

Reference: Ananthanarayan & Paniker's Textbook of Microbiology, 11th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.